Navigation in bile acid chemical space: Discovery of novel FXR and GPBAR1 ligands

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Finamore, Claudia ^a   Festa, Carmen ^a   Renga, Barbara ^b   Sepe, Valentina ^a   Carino, Adriana ^b   Masullo, Dario ^a   Biagioli, Michele ^b   Marchianò, Silvia ^b   Capolupo, Angela ^c   Monti, Maria Chiara ^c   Fiorucci, Stefano ^b   Zampella, Angela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Nuova Facoltà di Medicina   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; G PROTEIN COUPLED RECEPTOR; GASTROINTESTINAL AGENT; GPBAR1 PROTEIN, HUMAN;

AGONISTS; CHEMICAL STRUCTURE; HEK293 CELL LINE; HEP-G2 CELL LINE; HUMAN; METABOLISM; SYNTHESIS;

BILE ACIDS AND SALTS; GASTROINTESTINAL AGENTS; HEK293 CELLS; HEP G2 CELLS; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84978177085     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29320     Document Type: Article

References (39)

1. Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362-1365 (1999).
2. Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368 (1999).
3. Maruyama, T. et al. Identification of membrane type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719 (2002).
4. Modica, S., Gadaleta, R. M. & Moschetta, A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal. 8, e005 (2010).
5. Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 3, 543-553 (1999).
6. Goodwin, B. et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 6, 517-526 (2000).
7. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J. & Suchy, F. J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857-28865 (2001).
8. Boyer, J. L. et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1124-G1130 (2006).
9. Fiorucci, S. & Baldelli, F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol. 25, 252-259 (2009).
10. Fiorucci, S. et al. Targeting FXR in cholestasis: hype or hope. Expert Opin. Ther. Targets 12, 1449-1459 (2014).
11. Fiorucci, S., Mencarelli, A., Distrutti, E. & Zampella, A. Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med. Chem. 4, 877-891 (2012).
12. Beuers, U., Kremer, A. E., Bolier, R. & Elferink, R. P. Pruritus in cholestasis: facts and fiction. Hepatology 60, 399-407 (2014).
13. Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51, 771-784 (2010).
14. Rizzo, G. et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol. 70, 1164-1173 (2006).
15. Fiorucci, S., Rizzo, G., Donini, A., Distrutti, E. & Santucci, L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13, 298-309 (2007).
16. Mencarelli, A. et al. Dissociation of intestinal and hepatic activities of FXR and LXR? supports metabolic effects of terminal ileum interposition in rodents. Diabetes 62, 3384-3393 (2013).
17. Pean, N. et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology 58, 1451-1460 (2013).
18. Baghdasaryan, A. et al. Protective role of membrane bile acid receptor TGR5 (GPBAR1) in DDC-induced sclerosing cholangitis in mice. J. Hepatol. 60, S197-S198 (2014).
19. Alemi, F. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123, 1513-1530 (2013).
20. Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-489 (2006).
21. Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167-177 (2009).
22. Parker, H. E. et al. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br. J. Pharmacol. 165, 414-423 (2012).
23. Fiorucci, S., Mencarelli, A., Palladino, G. & Cipriani, S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30, 570-580 (2009).
24. Fiorucci, S., Cipriani, S., Baldelli, F. & Mencarelli, A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res. 49, 171-185 (2010).
25. D'Amore, C. et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J. Med. Chem. 57, 937-954 (2014).
26. Festa, C. et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J. Med. Chem. 57, 8477-8495 (2014).
27. Pellicciari, R. et al. 6-Ethylchenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002).
28. Rizzo, G. et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78, 617-630 (2010).
29. Pellicciari, R. et al. Non genomic actions of bile acids. Synthesis and preliminary characterization of 23-and 6, 23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J. Med. Chem. 50, 4265-4268 (2007).
30. Hirschfield, G. M. et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751-761 (2015).
31. Fiorucci, S., Zampella, A. & Distrutti, E. Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. Curr. Top. Med. Chem. 12, 605-624 (2012).
32. Sepe, V., Distrutti, E., Limongelli, V., Fiorucci, S. & Zampella, A. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. Future Med. Chem. 7, 1109-1135 (2015).
33. Di Leva, F. S. et al. Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism. Sci Rep. 5, 16605 (2015).
34. Cipriani, S. et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS One 10, e0129866 (2015).
35. Renga, B. et al. Reversal of endothelial dysfunction by GPBAR1 agonism in portal hypertension involves a AKT/FOXOA1 dependent regulation of H2S generation and endothelin-1. PLoS One 10, e0141082 (2015).
36. Sepe, V. et al. Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. Sci. Rep. 6, 19008 (2016).
37. Schteingart, C. D. & Hofmann, A. F. Synthesis of 24-nor-5 beta-cholan-23-oic acid derivatives: A convenient and efficient one-carbon degradation of the side chain of natural bile acids. J. Lipid Res. 10, 1387-1395 (1988).
38. Goto, J., Sano, Y., Chikai, T. & Nambara, T. Synthesis of disulfates of unconjugated and conjugated bile acids. Chem. Pharm. Bull. 35, 4562-4567(1987)
39. Song, X. et al. Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor. J. Lipid Res. 54, 3030-3044 (2013).